The sophisticated, new liquid biopsy test NavDx®measures fragments of DNA shed by cancers cells in the blood.
Ultra sensitive and quantitative method for non-invasive cancer detection.
We have developed an innovative, accurate, and sensitive blood test that can detect tumor-modified hpv dna
in patients. Our approach is to detect cancers using specialized genetic fingerprints of these cancers from circulating tumor DNA.
NavDx® is a blood test that detects human papilloma virus (HPV)-associated cancer by quantifying fragments of tumor-specific DNA shed by cells into the blood. NavDx® measures the number of tumor-tissue modified viral (TTMV™) HPV particles present in plasma cell-free DNA by digital droplet PCR (ddPCR). Importantly, NavDx® distinguishes TTMV™ from other, non-cancer associated sources of HPV DNA.